Skip to Content

User Reviews for Sandostatin LAR Depot

The following information is NOT intended to endorse drugs or recommend therapy. While these reviews might be helpful, they are not a substitute for the expertise, skill, knowledge and judgement of healthcare practitioners in patient care.

Learn more about Sandostatin LAR Depot.

Condition	Reviews	Compare	Avg. Ratings

Reviews for Sandostatin LAR Depot

For Diabetes, Type 1 "Great medicine. NO side effects."

9.0

Anonymous October 31, 2011

1 users found this comment helpful. Did you? Yes No

Report as inappropriate

Learn more about

More about Sandostatin LAR Depot (octreotide)

Consumer resources

Professional resources

Other formulations

Sandostatin

Related treatment guides

Drug Status

Availability Rx Prescription only

Pregnancy Category B No proven risk in humans

CSA Schedule N Not a controlled drug

Advancing Ovarian Cancer

FDA Consumer Updates

More FDA updates

Drug Class

Somatostatin and somatostatin analogs

Recently Approved

Amjevita Amjevita (adalimumab-atto) is biosimilar to Humira, an anti-TNF-α monoclonal antibody approved for ...
Exondys 51 Exondys 51 (eteplirsen) is an antisense oligonucleotide indicated for the treatment of Duchenne...
Kyleena Kyleena (levonorgestrel-releasing intrauterine system) is a low-dose progestin-containing...
Yosprala Yosprala (aspirin and omeprazole) is a platelet aggregation inhibitor and proton pump inhibitor...

Related News and Articles

FDA Issues Complete Response Letter for Mycapssa New Drug Application April 15, 2016

Related Questions & Answers

I can't find SANDOSTATIN LAR DEPOT locally unless I pay $2,000. Where can I find it & affordable?

Read more questions...

Drugs.com Discount Card

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include Micromedex® (updated Sep 2nd, 2016), Cerner Multum™ (updated Sep 5th, 2016), Wolters Kluwer™ (updated Aug 8th, 2016) and others. To view content sources and attributions, please refer to our editorial policy.